Showing results (91-100 of 169) with videos related to

Sort By:
Pageof 17
Targeted Oncology|July 14, 2017
Efficacy and Safety of Nintedanib Plus Docetaxel in Patients with Advanced Lung Adenocarcinoma: Complementary and Exploratory Analyses of the Phase III LUME-Lung 1 StudyMaya Gottfried, Jaafar Bennouna, Igor Bondarenko, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 12, 2012
Aflibercept and Docetaxel versus Docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trialRodryg Ramlau, Vera Gorbunova, Tudor Eliade Ciuleanu, et al.
Journal for Immunotherapy of Cancer|May 19, 2025
Interplay between sarcopenia, GDF-15, and the efficacy of nivolumab plus ipilimumab in patients with mismatch repair deficient metastatic colorectal cancer: final survival analysis of the phase II GERCOR NIPICOL studyLeonard Depotte, Paula Nay, Christophe Borg, et al.
Journal for Immunotherapy of Cancer|November 5, 2020
RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II studyRomain Cohen, Jaafar Bennouna, Aurélia Meurisse, et al.
JAMA Oncology|January 16, 2016
Prognostic Effect of BRAF and KRAS Mutations in Patients With Stage III Colon Cancer Treated With Leucovorin, Fluorouracil, and Oxaliplatin With or Without Cetuximab: A Post Hoc Analysis of the PETACC-8 TrialJulien Taieb, Aziz Zaanan, Karine Le Malicot, et al.
European Journal of Cancer (Oxford, England : 1990)|June 15, 2021
Predictive factors of severe early treatment-related toxicity in patients receiving first-line treatment for metastatic colorectal cancer: Pooled analysis of 2190 patients enrolled in Fédération Francophone de Cancérologie Digestive (FFCD) trialsClémence Breton, Thomas Aparicio, Karine Le Malicot, et al.
Journal for Immunotherapy of Cancer|June 26, 2020
Involvement of the M-CSF/IL-34/CSF-1R pathway in malignant pleural mesotheliomaThibaut Blondy, Sènan Mickael d'Almeida, Tina Briolay, et al.
JAMA Oncology|September 5, 2018
Safety and Efficacy of Bevacizumab Plus Standard-of-Care Treatment Beyond Disease Progression in Patients With Advanced Non-Small Cell Lung Cancer: The AvaALL Randomized Clinical TrialCesare Gridelli, Javier de Castro Carpeno, Anne-Marie C Dingemans, et al.
European Journal of Cancer (Oxford, England : 1990)|October 5, 2023
Time to recurrence and its relation to survival after recurrence in patients resected for stage III colon cancerCosimo Rasola, Pierre Laurent-Puig, Thierry André, et al.
Lung Cancer (Amsterdam, Netherlands)|June 11, 2015
Non-small cell lung cancer recurrence following surgery and perioperative chemotherapy: Comparison of two chemotherapy regimens (IFCT-0702: A randomized phase 3 final results study)Denis Moro-Sibilot, Clarisse Audigier-Valette, Patrick Merle, et al.
Pageof 17